Lumito enters into collaboration with CTC, strengthening its pathway to new customer projects in clinical research and drug development

Lumito AB (publ) ("Lumito" or the "Company") has entered into a collaboration with CTC Clinical Trial Consultants AB ("CTC"), a CRO company specialising in clinical research and drug development. Through this collaboration, CTC will be able to offer Lumito's SCIZYS® technology in relevant customer discussions and studies where sensitive and quantitative analysis of tissue samples can create value. A concrete customer dialogue is already underway with one of CTC's customers, together with Offspring Biosciences Sweden AB ("Offspring Biosciences"). For Lumito, the collaboration provides a new route to reaching a broader range of potential customer projects in clinical research and drug development.

During the development of new drugs, tissue samples can provide valuable information about how patients respond to treatment. SCIZYS® enables sensitive and quantitative analysis of specific biomarkers in tissue, including at low levels that are difficult to detect using conventional methods. This can provide important information for monitoring treatment response. For customers, this means access to a more detailed and reliable basis for decision-making when seeking to understand disease mechanisms, identify relevant biomarkers and evaluate the effects of different treatments.

CTC is a leading Clinical Research Organisation (CRO) in the life science industry. The company works closely with pharmaceutical developers and is well positioned to identify projects where this type of tissue analysis is relevant. By incorporating SCIZYS® into CTC's offering, Lumito gains access to a broader range of customer discussions, while potential customers can assess the technology's benefits in relation to their own research questions. The collaboration strengthens the link between SCIZYS® technology and concrete customer needs.

Together with Lumito's existing partner Offspring Biosciences, the parties can combine CTC's clinical trial services with Offspring Biosciences' specialist expertise in tissue analysis and SCIZYS® technology. This provides customers with an integrated workflow, from biopsy and sample handling to biomarker analysis and reporting, without requiring them to coordinate all the specialist functions themselves. This model is already being applied in an ongoing customer dialogue, in which Lumito acts as a subcontractor to Offspring Biosciences.

"The commercial value of SCIZYS® is realised when our analytical capabilities meet a specific need among drug developers. Through CTC, we can get closer to these needs, and together with Offspring Biosciences, we can contribute to an integrated workflow from sample to analytical report. The fact that this model is already being considered in a customer dialogue represents an important step towards translating the technology's potential into more customer projects" says Sanna Wallenborg, CEO of Lumito.

"We see a growing need for integrated solutions that combine clinical execution expertise with specialised analysis of biological samples. Through our collaboration with Lumito and Offspring Biosciences, we can complement our own expertise and offer our customers access to highly sensitive

tissue analysis within relevant clinical development projects" says Johanna Flygt, Sales Director at CTC.

The collaboration between Lumito and CTC originated following an initial meeting at Venture Road UK in June 2026.

About CTC
CTC is a full-service CRO company offering consultancy, planning, execution and reporting of clinical studies. The company has particular expertise in early clinical development and provides a broad range of services, including project management, clinical monitoring, medical writing, biometrics and clinical pharmacology. Through its own research clinics in Sweden and the Netherlands, CTC supports drug development and clinical research across several phases. Founded in 2011, the company works with both smaller innovative companies and international pharmaceutical companies. www.ctc-ab.se

About Offspring Biosciences
Offspring Biosciences is a specialized contract research organization (CRO) focused on cell- and tissue-based research and development. The company provides advanced analytical services to the pharmaceutical and biotechnology industries, including target validation, antibody characterization and translational research in human tissue. www.offspringbiosciences.se

About Lumito
Lumito develops and markets innovative technology that opens up new possibilities for advanced analysis of tissue samples in research, drug development and digital pathology.

The Company's patented SCIZYS® platform is based on upconverting nanoparticles (UCNPs) and combines very high detection sensitivity with minimal background interference. The technology enables the identification and quantitative analysis of specific proteins in tissue, even at low levels that may be difficult to detect using conventional methods. High signal stability and low background provide the basis for more detailed and reproducible tissue analysis.

SCIZYS® has the potential to support a shift from predominantly visual and semi-quantitative biomarker assessment to more sensitive, objective and quantitative analysis. This can provide researchers with new tools to understand disease mechanisms, identify biomarkers and develop more personalised treatment strategies.

Lumito's vision extends beyond current research applications. By providing more detailed information about biological processes, the Company aims to contribute to the development of precision medicine, in which better medicines, diagnostics and more informed treatment decisions may, over time, lead to improved patient outcomes and more efficient use of healthcare resources.

For more information, please contact:
Sanna Wallenborg, CEO
E-mail: sw@lumito.se
Phone: +46 70 870 01 68

Lumito

Seeing more. Enabling precision medicine.
Shaping the future of patient care.

www.lumito.se

SCIZYS® is intended for Research Use Only (RUO) and is not intended for clinical or diagnostic use.

Attachments
Lumito enters into collaboration with CTC, strengthening its pathway to new customer projects in clinical research and drug development